169 related articles for article (PubMed ID: 26450638)
21. Anterior Chamber Non-Hodgkin Lymphoma of the Iris Masquerading as Uveitis-Glaucoma-Hyphema Syndrome.
Gauthier AC; Nguyen A; Munday WR; Xu ML; Materin MA
Ocul Oncol Pathol; 2016 Oct; 2(4):230-233. PubMed ID: 27843901
[TBL] [Abstract][Full Text] [Related]
22. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
[TBL] [Abstract][Full Text] [Related]
23. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
24. Mantle Cell Lymphoma: A North Indian Tertiary Care Centre Experience.
Das ChK; Gogia A; Kumar L; Sharma A; Sharma MCh; Mallick SR
Asian Pac J Cancer Prev; 2016 Oct; 17(10):4583-4586. PubMed ID: 27892666
[TBL] [Abstract][Full Text] [Related]
25. Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant.
Bata BM; Pulido JS; Patel SV; Khan SP; Salomao D; Boyce TG; Bothun ED
J AAPOS; 2018 Apr; 22(2):159-161. PubMed ID: 29408337
[TBL] [Abstract][Full Text] [Related]
26. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response.
Crysandt M; Neumann B; Das M; Engelbertz V; Bendel M; Galm O; Osieka R; Jost E
Eur J Haematol; 2007 Dec; 79(6):546-9. PubMed ID: 17903214
[TBL] [Abstract][Full Text] [Related]
27. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
Berinstein NL; Mangel J
Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
[TBL] [Abstract][Full Text] [Related]
28. Anterior segment optical coherence tomography findings in leukemic iris infiltration.
Türkoğlu EB; Öcal O
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102578. PubMed ID: 34653699
[TBL] [Abstract][Full Text] [Related]
29. Mantle cell lymphoma in the ocular adnexal region.
Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.
de Smet MD; Vancs VS; Kohler D; Solomon D; Chan CC
Br J Ophthalmol; 1999 Apr; 83(4):448-51. PubMed ID: 10434868
[TBL] [Abstract][Full Text] [Related]
31. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
32. Blastic variant of mantle cell lymphoma following interfollicular Hodgkin's lymphoma.
Grosso LE; Collins BT; Visconti J
Leuk Lymphoma; 2001 May; 41(5-6):675-81. PubMed ID: 11378586
[TBL] [Abstract][Full Text] [Related]
33. Management of non Hodgkin's intraocular lymphoma with intravitreal methotrexate.
de Smet MD
Bull Soc Belge Ophtalmol; 2001; (279):91-5. PubMed ID: 11344720
[TBL] [Abstract][Full Text] [Related]
34. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
35. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
36. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
37. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
38. Classical type and blastoid variant mantle cell lymphoma in the same lymph node: Histology and cytological findings from a touch imprint specimen.
Nakatsuka SI; Nagatomo T; Nagano T; Goto T; Hashimoto K
Diagn Cytopathol; 2017 Apr; 45(4):364-370. PubMed ID: 28140514
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
40. [Treatment for mantle cell lymphoma].
Izutsu K
Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
